Research Paper Volume 16, Issue 3 pp 2866—2886

Figure 7. Multi-omics analysis. Analysis results of six immune cell infiltration algorithms in high and low risk groups (A). KEGG pathway enrichment analysis in high and low risk groups (B). Heatmap of clinicopathological features in high and low risk groups (C). Comparison of immunophenoscores (IPS) between high and low risk groups who have not been treated with anti-CTLA4 or anti-PD-1 immunotherapy (D), who have been treated with anti-CTLA4 and anti-PD-1 immunotherapy (E), who have been treated with anti-CTLA4 and anti-PD-1 immunotherapy, who have only been treated with anti-PD-1 immunotherapy (F), and who have only been treated with anti-CTLA4 immunotherapy (G). Comparison of TIDE (H), Dysfunction (I), Exclusion (J), CAF (K) between high and low risk groups.